Shares of Novavax declined after the company reaffirmed full-year revenue and fellow vaccine maker Moderna lowered its guidance. Novavax stock was down 7.3%, to $8.64, on Monday but is up about 89% ...

Moderna continues to cut costs, which could raise questions about the vaccine playbook used during the Covid-19 pandemic.

Key US equity benchmarks slid on Monday as major tech stocks continued their fall, while bond yields continue to rise.

The Cambridge-based company said it expects 2025 revenue of between $1.5 billion to $2.5 billion, down from its previous ...

Moderna stock crashed Monday after the firm slashed its outlooks for 2024 and 2025, and announced an expanded cost-cutting ...

Moderna stock crashed Monday after the firm slashed its outlooks for 2024 and 2025, and announced an expanded cost-cutting ...

Moderna lost more than $3 billion in maker value after cutting its forecast for 2025 revenue from its COVID-19 and RSV ...

Moderna's stock plummeted to an almost five-year low after the biotech company cut its revenue outlook for this year and said that sales for last year will come in at the lower end of its guidance.

U.S. equities were mixed at midday, with the Nasdaq losing more than 1% on worries about future Federal Reserve interest-rate cuts.

Shares of Moderna dropped more than 20% intraday to $33.44, more than erasing gains last week after the first bird-flu death ...

Moderna 's ( MRNA -21.95%) sales are slowing down, and Moderna stock is going down -- a lot. The coronavirus vaccine maker's ...

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions ...